How the LDT Final Rule’s Exemptions Apply to Oncology Labs
Regulatory expert explores whether any exclusions might benefit cancer laboratories trying to navigate upcoming compliance deadlines
Regulatory expert explores whether any exclusions might benefit cancer laboratories trying to navigate upcoming compliance deadlines
As we move further into 2023, COVID-19, add-on, and genetic tests will likely remain targets for federal regulators.
A new OIG Advisory Opinion sheds some light on how to properly structure these arrangements in a hospital inpatient setting.
Recent fraud case involving phlebotomy company shows why labs need to pay special attention to Medicare specimen collection and travel allowance rules.
A look at the US end-of-emergency game plan and how it will impact lab compliance.
Sales and marketing operations liability risks and the measures labs should and shouldn’t take to manage those risks.
Economic volatility and uncertainty is also making a significant impact on merger and acquisition activity in the diagnostics space.
An effective business case communicates need, benefit, and risks.
Abbott and Roche garnered the lion’s share of new 510(k) lab test approvals in 2022.
There were three notable CDx alliances announced in January 2023, all of which involved cancer-related solutions.
According to a new report, tough macro-economic conditions caused digital health fundraising levels to fall off dramatically in 2022.